$ALAB

Dyckerhoff Stefan A sold $1.1M of ALAB

Dyckerhoff Stefan A sold 3,505 shares of Astera Labs, Inc. (ALAB) at an average of $311.83 ($309.29–$313.07, $1.09M total) across 3 trades on 2026-08-06 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Dyckerhoff Stefan A
Published Aug 10, 2026, 8:17 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 10, 2026, 8:30 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$ALAB
Neutral
medium confidence
Mentioned
$ALAB
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ALABNeutralLow
01

Why it matters

The only new information is the director’s sale size, price range, and remaining holdings after the transaction; it does not include any accompanying corporate or business update.

02

Market read

Traders may note the insider sale for sentiment, but the 10b5-1 structure makes it a low-signal catalyst.

03

What to watch

The filing does not disclose any new company fundamentals, guidance, or operational changes; it only provides transaction details and post-sale holdings.

Relevance 5/10Novelty 3/10Timing: Filed 2026-08-10 after the 2026-08-06 sale trades were executed.

Background

The article is an SEC Form 4 insider transaction disclosure for Astera Labs, Inc. (ALAB).

Company-level read

Ticker impact

$ALABNeutralMedium confidence
Context

Astera Labs director Stefan Dyckerhoff sold 3,505 shares in open-market trades for about $1.09M under a pre-arranged 10b5-1 plan.

Expected impact

Low likelihood of a sustained price move solely from this filing; any impact is likely short-lived.

Evidence & confidence

The transaction is an open-market sale by a director and explicitly tied to a pre-arranged 10b5-1 plan, which typically reduces interpretive value versus discretionary selling.

Market effects

No clear sector read-through from a single director 10b5-1 sale.

None indicated.

None indicated.

Counterpoint

Because the sale is under a pre-arranged 10b5-1 plan, it may reflect scheduled liquidity needs rather than bearish expectations.

Key entities

  • Astera Labs, Inc.

    US-listed company whose director insider sale is disclosed on Form 4.

  • Dyckerhoff Stefan A

    Director who executed open-market sales under a pre-arranged 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ALABMed

ALAB Stock Holds Support As High Valuation Tests Traders

Astera Labs Inc. (ALAB) stock rose 6.54% due to strong AI infrastructure demand. The company reported $392.4M in quarterly revenue, $153.1M in net income, and $67.2M in free cash flow. ALAB trades at 127x earnings and 37x sales, with a strong balance sheet but high valuation concerns. Traders are watching key price levels around $262–$265 and $272–$275.

$ALABMed

ALAB Broadens Leo Portfolio: Can It Stay Ahead of MRVL & CRDO?

Astera Labs (ALAB) reported record Q2 2026 revenue growth, driven by AI connectivity products. The company expanded its Leo CXL memory controller portfolio, gaining hyperscaler traction. Q3 2026 revenue is expected between $540M and $560M. Competitors Marvell (MRVL) and Credo (CRDO) are also advancing in AI connectivity. ALAB shares rose 51.8% YTD, with a forward P/S of 16.16X.

$ALABMed

Why Is Astera Labs Stock Down Today?

Astera Labs (NASDAQ: ALAB) shares dropped 10.1% on Sept. 14, 2026, after AI leaders called for slower AI development, threatening demand for its data-center networking products. The decline was steeper than the S&P 500's 0.3% and Nasdaq's 0.1% drops.

$ALABMed

Astera Labs’ Scorpio X Is Already in Volume Production. Citi Showed How Fast the Customer List Is Growing

Astera Labs (ALAB) announced its Scorpio X product line is in volume production and expects revenue growth, with customer engagements increasing. The company guided Q3 revenue to $540M-$560M. Shares dropped after missing S&P 500 inclusion. Analysts set a mid-target price of ~$715, citing potential total return of ~146%. Risks include customer concentration and valuation multiple compression.

$ALABMed

ALAB Gains From Aries and Taurus Strength: Can It Beat MRVL & CRDO?

Astera Labs (ALAB) reports strong Q2 2026 revenue growth driven by demand for Aries and Taurus connectivity solutions, with PCIe 6 products accounting for over 50% of total revenue. The company expects Q3 2026 revenues of $540M-$560M, up 40% sequentially. ALAB competes with Marvell (MRVL) and Credo (CRDO) in the AI connectivity market. ALAB's stock has surged 73.7% YTD, with a forward P/S of 18.64x.